Are unexplained adverse health events following HPV vaccination associated with infectious mononucleosis? - A Danish nationwide matched case-control study.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
31 07 2020
Historique:
received: 03 02 2020
revised: 12 06 2020
accepted: 18 06 2020
pubmed: 7 7 2020
medline: 28 4 2021
entrez: 7 7 2020
Statut: ppublish

Résumé

In Denmark, the acceptance of the HPV vaccination program has been threatened by reports of suspected adverse events. Epstein Barr Virus (EBV) infection is associated with symptoms of long-lasting tiredness and may be misinterpreted as HPV vaccine adverse events. The main aim of this study was to examine if EBV infection around time of HPV vaccination was a risk factor for later suspected vaccine adverse events. The study was a nationwide register-based matched case-control study. Cases were females vaccinated against HPV in the period 2011 throughout 2017 with suspected adverse events. For each case, five HPV vaccinated females without suspected adverse events were selected. Information about EBV infection was obtained from the Danish Microbiology Database and assessed for three time periods: (1) before first HPV vaccination, (2) around time of HPV vaccination, and (3) any time during the study period 2010-2017. Multiple logistic regression was used to estimate the association between EBV and suspected adverse events. We identified 1217 cases, matched to 6085 controls. A higher proportion of cases (38; 3.1%) than controls (31; 0.5%) were tested for EBV around time of HPV vaccination and cases had elevated odds for testing both EBV positive (OR 4.52, 95% CI 2.68-7.63) and EBV negative (OR 20.99, 95% CI 5.81-75.79). Only five females were classified with acute/recent EVB infection in this period. Misinterpretation of EBV infection late symptoms is not a leading explanation for Danish females experiencing suspected adverse events after HPV vaccination. Although EBV cannot be excluded as an explanatory factor for a very small proportion of suspected adverse events, the findings are more likely explained by protopathic bias, i.e. the fact that a larger proportion of females suspecting adverse events are tested for EBV.

Sections du résumé

BACKGROUND
In Denmark, the acceptance of the HPV vaccination program has been threatened by reports of suspected adverse events. Epstein Barr Virus (EBV) infection is associated with symptoms of long-lasting tiredness and may be misinterpreted as HPV vaccine adverse events. The main aim of this study was to examine if EBV infection around time of HPV vaccination was a risk factor for later suspected vaccine adverse events.
METHODS
The study was a nationwide register-based matched case-control study. Cases were females vaccinated against HPV in the period 2011 throughout 2017 with suspected adverse events. For each case, five HPV vaccinated females without suspected adverse events were selected. Information about EBV infection was obtained from the Danish Microbiology Database and assessed for three time periods: (1) before first HPV vaccination, (2) around time of HPV vaccination, and (3) any time during the study period 2010-2017. Multiple logistic regression was used to estimate the association between EBV and suspected adverse events.
RESULTS
We identified 1217 cases, matched to 6085 controls. A higher proportion of cases (38; 3.1%) than controls (31; 0.5%) were tested for EBV around time of HPV vaccination and cases had elevated odds for testing both EBV positive (OR 4.52, 95% CI 2.68-7.63) and EBV negative (OR 20.99, 95% CI 5.81-75.79). Only five females were classified with acute/recent EVB infection in this period.
CONCLUSION
Misinterpretation of EBV infection late symptoms is not a leading explanation for Danish females experiencing suspected adverse events after HPV vaccination. Although EBV cannot be excluded as an explanatory factor for a very small proportion of suspected adverse events, the findings are more likely explained by protopathic bias, i.e. the fact that a larger proportion of females suspecting adverse events are tested for EBV.

Identifiants

pubmed: 32624249
pii: S0264-410X(20)30843-4
doi: 10.1016/j.vaccine.2020.06.057
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5678-5684

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lene Wulff Krogsgaard (LW)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: l.krogsgaard@ph.au.dk.

Ida Glode Helmuth (IG)

Department of Infectious Diseases Epidemiology, Statens Serum Institut, Copenhagen, Denmark. Electronic address: IDGK@ssi.dk.

Bodil Hammer Bech (BH)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: bhb@ph.au.dk.

Oleguer Plana-Ripoll (O)

National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus University, Denmark. Electronic address: opr@econ.au.dk.

Tina Hovgaard Lützen (TH)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: tina.lutzen@ph.au.dk.

Hanne Thang Vestergaard (HT)

Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.

Karsten Dalsgaard Bjerre (KD)

Division of Infectious Disease Preparedness, Data Analysis and Integration, Statens Serum Institut, Copenhagen, Denmark. Electronic address: KADB@ssi.dk.

Reimar Wernich Thomsen (RW)

Department of Clinical Epidemiology, Aarhus University Hospital, Denmark. Electronic address: rwt@clin.au.dk.

Kåre Mølbak (K)

Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark; Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark. Electronic address: KRM@SSI.dk.

Dorte Rytter (D)

Research Unit for Epidemiology, Department of Public Health, Aarhus University, Denmark. Electronic address: dr@ph.au.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH